These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

155 related items for PubMed ID: 17420212

  • 1. Lysostaphin in treatment of neonatal Staphylococcus aureus infection.
    Oluola O, Kong L, Fein M, Weisman LE.
    Antimicrob Agents Chemother; 2007 Jun; 51(6):2198-200. PubMed ID: 17420212
    [Abstract] [Full Text] [Related]

  • 2. Treatment of methicillin-resistant Staphylococcus aureus in neonatal mice: lysostaphin versus vancomycin.
    Placencia FX, Kong L, Weisman LE.
    Pediatr Res; 2009 Apr; 65(4):420-4. PubMed ID: 19127212
    [Abstract] [Full Text] [Related]

  • 3. Lysostaphin treatment of methicillin-resistant Staphylococcus aureus keratitis in the rabbit.
    Dajcs JJ, Hume EB, Moreau JM, Caballero AR, Cannon BM, O'Callaghan RJ.
    Invest Ophthalmol Vis Sci; 2000 May; 41(6):1432-7. PubMed ID: 10798659
    [Abstract] [Full Text] [Related]

  • 4. Extension of nasal anti-Staphylococcus aureus efficacy of lysostaphin by its incorporation into a chitosan-o/w cream.
    Cui F, Li G, Huang J, Zhang J, Lu M, Lu W, Huang Q.
    Drug Deliv; 2010 Nov; 17(8):617-23. PubMed ID: 20726810
    [Abstract] [Full Text] [Related]

  • 5. Sustained anti-staphylococcal effect of lysostaphin in the rabbit aqueous humor.
    Balzli CL, McCormick CC, Caballero AR, O'Callaghan RJ.
    Curr Eye Res; 2010 Jun; 35(6):480-6. PubMed ID: 20465441
    [Abstract] [Full Text] [Related]

  • 6. Lysostaphin as a treatment for systemic Staphylococcus aureus infection in a mouse model.
    Kokai-Kun JF, Chanturiya T, Mond JJ.
    J Antimicrob Chemother; 2007 Nov; 60(5):1051-9. PubMed ID: 17848374
    [Abstract] [Full Text] [Related]

  • 7. The effectiveness of lysostaphin therapy for experimental coagulase-negative Staphylococcus endophthalmitis.
    McCormick CC, Dajcs JJ, Reed JM, Marquart ME, O'Callaghan RJ.
    Curr Eye Res; 2006 Mar; 31(3):225-30. PubMed ID: 16531279
    [Abstract] [Full Text] [Related]

  • 8. Immunity to lysostaphin and its therapeutic value for ocular MRSA infections in the rabbit.
    Dajcs JJ, Thibodeaux BA, Girgis DO, Shaffer MD, Delvisco SM, O'Callaghan RJ.
    Invest Ophthalmol Vis Sci; 2002 Dec; 43(12):3712-6. PubMed ID: 12454041
    [Abstract] [Full Text] [Related]

  • 9. Lysostaphin is effective in treating methicillin-resistant Staphylococcus aureus endophthalmitis in the rabbit.
    Dajcs JJ, Thibodeaux BA, Hume EB, Zheng X, Sloop GD, O'Callaghan RJ.
    Curr Eye Res; 2001 Jun; 22(6):451-7. PubMed ID: 11584345
    [Abstract] [Full Text] [Related]

  • 10. In vitro activity of lysostaphin, mupirocin, and tea tree oil against clinical methicillin-resistant Staphylococcus aureus.
    LaPlante KL.
    Diagn Microbiol Infect Dis; 2007 Apr; 57(4):413-8. PubMed ID: 17141452
    [Abstract] [Full Text] [Related]

  • 11. Lysostaphin eradicates established Staphylococcus aureus biofilms in jugular vein catheterized mice.
    Kokai-Kun JF, Chanturiya T, Mond JJ.
    J Antimicrob Chemother; 2009 Jul; 64(1):94-100. PubMed ID: 19398455
    [Abstract] [Full Text] [Related]

  • 12. [Methicillin-resistant Staphylococcus aureus infection and its treatment in burned patients].
    Huan JN, Chen YL, Ge SD.
    Zhonghua Wai Ke Za Zhi; 1994 Apr; 32(4):244-5. PubMed ID: 7842932
    [Abstract] [Full Text] [Related]

  • 13. In vivo efficacy of the antimicrobial peptide ranalexin in combination with the endopeptidase lysostaphin against wound and systemic meticillin-resistant Staphylococcus aureus (MRSA) infections.
    Desbois AP, Gemmell CG, Coote PJ.
    Int J Antimicrob Agents; 2010 Jun; 35(6):559-65. PubMed ID: 20206480
    [Abstract] [Full Text] [Related]

  • 14. Bioluminescence and 19F magnetic resonance imaging visualize the efficacy of lysostaphin alone and in combination with oxacillin against Staphylococcus aureus in murine thigh and catheter-associated infection models.
    Hertlein T, Sturm V, Lorenz U, Sumathy K, Jakob P, Ohlsen K.
    Antimicrob Agents Chemother; 2014 Jun; 58(3):1630-8. PubMed ID: 24366730
    [Abstract] [Full Text] [Related]

  • 15. Lysostaphin: an antistaphylococcal agent.
    Kumar JK.
    Appl Microbiol Biotechnol; 2008 Sep; 80(4):555-61. PubMed ID: 18607587
    [Abstract] [Full Text] [Related]

  • 16. Lysostaphin-coated titan-implants preventing localized osteitis by Staphylococcus aureus in a mouse model.
    Windolf CD, Lögters T, Scholz M, Windolf J, Flohé S.
    PLoS One; 2014 Sep; 9(12):e115940. PubMed ID: 25536060
    [Abstract] [Full Text] [Related]

  • 17. Effects of lysostaphin on Staphylococcus aureus infections of the mouse mammary gland.
    Bramley AJ, Foster R.
    Res Vet Sci; 1990 Jul; 49(1):120-1. PubMed ID: 2382049
    [Abstract] [Full Text] [Related]

  • 18. Lysostaphin: use of a recombinant bactericidal enzyme as a mastitis therapeutic.
    Oldham ER, Daley MJ.
    J Dairy Sci; 1991 Dec; 74(12):4175-82. PubMed ID: 1787188
    [Abstract] [Full Text] [Related]

  • 19. Efficacy of Telavancin in a rabbit model of aortic valve endocarditis due to methicillin-resistant Staphylococcus aureus or vancomycin-intermediate Staphylococcus aureus.
    Madrigal AG, Basuino L, Chambers HF.
    Antimicrob Agents Chemother; 2005 Aug; 49(8):3163-5. PubMed ID: 16048918
    [Abstract] [Full Text] [Related]

  • 20. [Topical use of lysostaphin for Staphylococcus aureus infection of burn wounds in mice].
    Huan JN.
    Zhonghua Wai Ke Za Zhi; 1992 May; 30(5):270-1, 316. PubMed ID: 1289000
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 8.